Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241306 | 1.00 | PGR (0.45) | PGRCYP2D6CYP2C9GPR119NR1H4 | |
| SCHEMBL4243356 | 0.83 | CCR5 (0.45) | PGRCYP2D6CYP2C9NR1H4 | |
| SCHEMBL4243359 | 0.83 | CCR5 (0.45) | PGRCYP2D6CYP2C9NR1H4 | |
| SCHEMBL4242924 | 0.83 | GPR119 (0.48) | PGRCYP2D6CYP2C9GPR119MEN1 | |
| SCHEMBL4586039 | 0.82 | PGR (0.40) | PGRCYP2D6CYP2C9NR1H4 | |
| SCHEMBL4244992 | 0.79 | SLC6A2 (0.50) | PGRCYP2D6CYP2C9GPR119 | |
| SCHEMBL4241224 | 0.76 | CCR5 (0.56) | — | |
| SCHEMBL4241217 | 0.76 | CCR5 (0.56) | — | |
| SCHEMBL4586706 | 0.76 | CCR5 (0.40) | PGRCYP2D6CYP2C9NR1H4 | |
| SCHEMBL14270985 | 0.70 | GPR119 (0.58) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | PGR 976/4885CYP2D6 3964/4885CYP2C9 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.